 |
| 26-Apr-13 | Reiterated |
MKM Partners |
Sell |
$26 → $29 |
|
| 15-Apr-13 | Reiterated |
Barclays |
Equal Weight |
$33 → $42 |
|
| 25-Jan-13 | Reiterated |
UBS |
Neutral |
$34 → $36 |
|
| 09-Jan-12 | Reiterated |
Barclays Capital |
Overweight |
$34 → $36 |
|
| 19-Oct-11 | Initiated |
MKM Partners |
Sell |
$26 |
|
| 27-Jun-11 | Reiterated |
UBS |
Neutral |
$28 → $30 |
|
| 31-Mar-11 | Downgrade |
Jefferies |
Buy → Hold |
$28.50 |
|
| 28-Mar-11 | Reiterated |
Barclays Capital |
Overweight |
$28 → $30 |
|
| 22-Sep-10 | Reiterated |
Deutsche Bank |
Buy |
$28 → $31.50 |
|
| 01-Sep-10 | Reiterated |
UBS |
Neutral |
$26 → $27 |
|
| 31-Aug-10 | Upgrade |
Jefferies |
Hold → Buy |
$28.80 → $30 |
|
| 12-Mar-10 | Initiated |
Jefferies & Co |
Hold |
$27 |
|
| 16-Dec-09 | Initiated |
UBS |
Neutral |
|
|
| 09-Oct-09 | Initiated |
Wells Fargo |
Outperform |
|
|
| 03-Apr-09 | Downgrade |
Bernstein |
Outperform → Mkt Perform |
|
|
| 10-Dec-08 | Upgrade |
Citigroup |
Hold → Buy |
$25 |
|
| 07-Aug-08 | Reiterated |
Argus |
Buy |
$30 → $27 |
|
| 18-Jul-08 | Initiated |
Citigroup |
Hold |
$23 |
|
| 25-Jun-08 | Initiated |
JP Morgan |
Neutral |
|
|
| 04-Jun-08 | Downgrade |
Cowen & Co |
Outperform → Neutral |
|
|
|
 |
| 24-May-13 06:03PM | Final Glance: Pharmaceuticals companies AP |
| 04:10PM | Promising Data on ONCY's Reolysin Zacks |
| 03:40PM | Oncogenex to Advance OGX-427 Development Zacks |
| 03:21PM | Bristol-Myers Squibb (BMY) Shares Cross 3% Yield Mark at Forbes |
| 02:10PM | Why Immunotherapy Stocks Could Be Set for a Big Move at Motley Fool |
| 01:17PM | Midday Glance: Pharmaceuticals companies AP |
| 12:15PM | [video] Gold on Track for Best Weekly Gain at CNBC |
| 10:33AM | Early Glance: Pharmaceuticals companies AP |
| 23-May-13 08:28PM | P&G Timeline: From Lafley to McDonald to Lafley, Again at The Wall Street Journal |
| 06:25PM | Alkermes Earnings Beat Estimates, But Outlook Unclear at Investor's Business Daily |
| 06:04PM | Final Glance: Pharmaceuticals companies AP |
| 03:53PM | This Fund's Islamic Values Also Mean Strong Returns at Barrons.com |
| 01:52PM | Alkermes Stock Seesaws After Q4 Beat, Guidance Miss at Investor's Business Daily |
| 01:47PM | Midday Glance: Pharmaceuticals companies AP |
| 12:44PM | Alkermes posts 4Q profit as royalty payments rise AP |
| 12:31PM | Workday Says Getting Customers From Oracle, SAP at Investor's Business Daily |
| 10:46AM | Early Glance: Pharmaceuticals companies AP |
| 10:41AM | Wall Street Loves this New Immunotherapy Cancer Drug at Motley Fool |
| 09:46AM | J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizer at Forbes |
| 08:09AM | Today's Market News To Trade On: 5 Stocks Moving On News at Seeking Alpha |
| 04:16AM | Bristol-Myers gets vote of confidence optionMONSTER |
| 22-May-13 06:35PM | Can Financial Innovation Unlock a Cure for Cancer? at Motley Fool +5.31% |
| 06:08PM | Final Glance: Pharmaceuticals companies AP |
| 05:53PM | Bristol-Myers, Jazz Pharmaceuticals Lead Pharma Rally at Investor's Business Daily |
| 05:37PM | U.S. stocks drop on Fed tapering worries at MarketWatch |
| 05:15PM | Today's 3 Best Stocks at Motley Fool |
| 05:02PM | Wall Street falters in volatile session on Fed worries Reuters |
| 04:45PM | U.S. stocks drop on Fed tapering worries at MarketWatch |
| 04:30PM | Wall Street falters in volatile session on Fed worries Reuters |
| 04:25PM | US STOCKS-Wall St falters in volatile session on Fed worries at Reuters |
| 04:25PM | Wednesdays movers: Saks rallies for third day at MarketWatch |
| 04:25PM | Stocks Reverse Course, Drop on Worries of Fed Pullback at TheStreet |
| 04:08PM | Stocks Tumble Nearly 1% on Fed Tapering Fears at CNBC |
| 03:55PM | Gilead's Sofosbuvir under European Review Zacks |
| 03:54PM | Alkermes Earnings Seen Rising, But Sales Uncertain at Investor's Business Daily |
| 03:45PM | Jim Simons' top stock holdings at MarketWatch |
| 03:34PM | U.S. stocks drop on Fed tapering worries at MarketWatch |
| 03:24PM | Stocks Drop 1% as Fed Minutes Hint at Tapering at CNBC |
| 03:07PM | US STOCKS-Wall St declines as FOMC minutes raise concern over Fed tapering at Reuters |
| 02:51PM | U.S. stocks drop on Fed tapering worries at MarketWatch |
| 02:10PM | Stocks Fall After Fed Minutes Hint at Tapering at CNBC |
| 02:06PM | Wednesdays movers: Saks rallies for third day at MarketWatch |
| 02:02PM | US STOCKS-Wall St little changed as investors weigh Bernanke comments at Reuters |
| 01:40PM | Analysts: Home Depot Shares Still Look Good and 3 More Research Notes to Browse at Wall St. Cheat Sheet |
| 01:38PM | Stocks Lose Steam as Techs Turn Lower at CNBC |
| 01:18PM | Buy Bristol-Myers, Says Citi; Stock Jumps 7% at Barrons.com |
| 01:18PM | NYSE stocks posting largest percentage increases AP |
| 01:18PM | Most active New York Stock Exchange-traded stocks AP |
| 01:17PM | Midday Glance: Pharmaceuticals companies AP |
| 12:43PM | U.S. stocks hold gains after Bernanke bond talk at MarketWatch |
| 12:40PM | Stocks Advance as Bernanke Signals No Change to Stimulus at TheStreet |
| 12:38PM | 6 things you missed as Bernanke hogged the airwaves at MarketWatch |
| 12:09PM | Stocks Stage Broad Advance; Bristol-Myers Leads Medicals at Investor's Business Daily |
| 12:08PM | [video] Bernanke Spurs Stocks at TheStreet |
| 11:51AM | Wednesdays movers: Drug makers lead S&P 500 at MarketWatch |
| 11:46AM | Is There Value In Today's Stock Market? at Seeking Alpha |
| 11:16AM | Apples iPhone Sales, Bristol-Myers Gets Upgraded, and 3 More Hot Stocks at Wall St. Cheat Sheet |
| 11:13AM | Bristol-Myers Squibb Reaches New 52-Week High (BMY) at TheStreet |
| 11:09AM | US STOCKS-Wall Street rises as concern eases over Fed tapering at Reuters |
| 11:04AM | Bristol-Myers shares jump on 'beginning of the end of cancer' at MarketWatch |
| 10:51AM | Early Glance: Pharmaceuticals companies AP |
| 10:33AM | Bristol-Myers jumps after Citi ups rating on cancer potential at theflyonthewall.com |
| 10:33AM | Stocks Gain as Bernanke Signals No Changes to Fed Stimulus at TheStreet |
| 10:00AM | On The Fly: Analyst Upgrade Summary at theflyonthewall.com |
| 09:53AM | [video] Cramer's Six in 60: SodaStream at CNBC |
| 09:19AM | Stock Upgrades: Dice Holdings Is on a Roll at Minyanville |
| 08:35AM | Ahead of the Bell: Analyst upgrades Bristol-Myers AP |
| 05:33AM | Immune system cancer drugs tipped to be a $35 bln market at Reuters |
| 21-May-13 08:50PM | Final Glance: Pharmaceuticals companies AP |
| 03:13PM | Bristol-Myers Squibb's Management Presents at UBS Global Healthcare Services Conference (Transcript) Seeking Alpha |
| 03:05PM | Roche, Reloaded at Investopedia |
| 02:28PM | The Top 3 Diseases Caused by Stress at Motley Fool |
| 01:16PM | Midday Glance: Pharmaceuticals companies AP |
| 11:45AM | After A Big Rally, Pfizer Might Need Some Rest at Investopedia |
| 11:37AM | Cramer: Buy BioMarin Pharma, Bristol-Myers Squibb, Asbury Automotive, But Sell These 2 Stocks at Wall St. Cheat Sheet |
| 10:36AM | Early Glance: Pharmaceuticals companies AP |
| 09:40AM | Bristol-Myers Squibb Director Sells More Than 215K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet |
| 06:00AM | Cramer's Top Stock Picks: SAVE GILD BMY HTA TSLA at TheStreet |
| 20-May-13 06:26PM | Cramer's Watch List Ahead of Big Cancer Conference at CNBC |
| 06:25PM | [video] The War Against Cancer at CNBC |
| 06:05PM | Final Glance: Pharmaceuticals companies AP |
| 05:01PM | Teva Bets on Reformulating Old Drugs as Investors Say Show Me at Bloomberg |
| 04:34PM | Bristol Myers Squibb And The New Wave Of Cancer Drugs at Seeking Alpha |
| 01:44PM | Will Amgen's Novel Drug Revolutionize Cancer Treatment? at Motley Fool |
| 01:17PM | Midday Glance: Pharmaceuticals companies AP |
| 01:03PM | 5 Drugs Stocks On The Rise at TheStreet |
| 12:01PM | 1 Pioneering Device to Jump-Start the Cardiovascular Industry at Motley Fool |
| 10:33AM | Early Glance: Pharmaceuticals companies AP |
| 10:03AM | Shire advances after report renews takeover speculation at theflyonthewall.com |
| 09:01AM | [video] Monday's Market Roadmap at CNBC |
| 06:30AM | Leerink estimates Shire takeout value at least $110 per share at theflyonthewall.com |
| 06:25AM | Shire may return cash to thwart takeover, Daily Mail reports theflyonthewall.com |
| 19-May-13 09:10PM | Shades Of 1999 at Seeking Alpha |
| 04:43PM | Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin at Seeking Alpha |
| 11:00AM | Pick Your Poison: Overweight or High Cholesterol at Motley Fool |
| 08:11AM | PRESS DIGEST - Sunday British business - May 19 at Reuters |
| 18-May-13 12:45PM | 1 Giant Leap for MannKind at Motley Fool |
| 17-May-13 08:52PM | Oncothyreon A Speculative Buy at Seeking Alpha |
| 06:03PM | Final Glance: Pharmaceuticals companies AP |
| 05:00PM | Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Winner at TheStreet |
|
 |
| Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. |
 |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Caforio Giovanni | Pres., US Pharmaceuticals | May 23 | Option Exercise | 25.45 | 21,333 | 542,925 | 84,501 | May 23 05:19 PM | | Cazala Beatrice J | EVP Commercial Operations | May 23 | Option Exercise | 23.90 | 116,412 | 2,782,247 | 382,657 | May 23 05:20 PM | | Caforio Giovanni | Pres., US Pharmaceuticals | May 23 | Sale | 46.29 | 26,647 | 1,233,490 | 57,854 | May 23 05:19 PM | | Cazala Beatrice J | EVP Commercial Operations | May 23 | Sale | 46.99 | 96,000 | 4,511,040 | 286,657 | May 23 05:20 PM | | CORNELIUS JAMES M | Director | May 17 | Option Exercise | 22.14 | 205,996 | 4,560,751 | 957,820 | May 20 04:17 PM | | CORNELIUS JAMES M | Director | May 17 | Sale | 42.98 | 215,996 | 9,283,708 | 741,824 | May 20 04:17 PM | | CORNELIUS JAMES M | Director | May 16 | Sale | 43.24 | 10,000 | 432,400 | 751,824 | May 20 04:17 PM | | DANIELS BRIAN | SVP Global Dev & Med Affairs | May 08 | Sale | 39.93 | 15,000 | 598,950 | 63,239 | May 08 04:25 PM | | CORNELIUS JAMES M | Director | May 08 | Sale | 39.78 | 10,000 | 397,800 | 761,824 | May 09 04:19 PM | | CORNELIUS JAMES M | Director | May 07 | Sale | 39.91 | 10,000 | 399,100 | 771,824 | May 09 04:19 PM | | ANDREOTTI LAMBERTO | Chief Executive Officer | May 04 | Option Exercise | 0.00 | 13,989 | 0 | 582,457 | May 07 06:29 PM | | CORNELIUS JAMES M | Director | May 02 | Sale | 39.85 | 10,000 | 398,500 | 781,824 | May 02 05:01 PM | | Moed Samuel J | SVP, Strat Plan & Analysis | May 01 | Option Exercise | 0.00 | 5,000 | 0 | 25,754 | May 02 04:23 PM | | CORNELIUS JAMES M | Director | May 01 | Sale | 39.66 | 10,000 | 396,600 | 791,824 | May 02 05:01 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Apr 30 | Option Exercise | 24.98 | 305,905 | 7,641,575 | 459,398 | May 01 05:58 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Apr 30 | Sale | 39.61 | 353,509 | 14,004,254 | 105,889 | May 01 05:58 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Apr 30 | Sale | 39.65 | 2,297 | 91,076 | 9,091 | May 01 05:58 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Apr 29 | Option Exercise | 24.03 | 73,390 | 1,763,821 | 258,411 | May 01 05:58 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Apr 29 | Sale | 39.92 | 104,918 | 4,188,026 | 153,493 | May 01 05:58 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Apr 29 | Sale | 39.97 | 45,783 | 1,829,947 | 9,550 | May 01 05:58 PM | | CORNELIUS JAMES M | Director | Apr 26 | Sale | 40.12 | 10,000 | 401,200 | 801,824 | Apr 29 04:22 PM | | CORNELIUS JAMES M | Director | Apr 25 | Sale | 40.34 | 10,000 | 403,400 | 811,824 | Apr 29 04:22 PM | | CORNELIUS JAMES M | Director | Apr 17 | Sale | 40.75 | 10,000 | 407,500 | 821,824 | Apr 18 04:18 PM | | CORNELIUS JAMES M | Director | Apr 16 | Sale | 40.82 | 10,000 | 408,200 | 831,824 | Apr 18 04:18 PM | | CORNELIUS JAMES M | Director | Apr 11 | Sale | 41.31 | 10,000 | 413,100 | 841,824 | Apr 11 05:13 PM | | CORNELIUS JAMES M | Director | Apr 10 | Sale | 40.99 | 10,000 | 409,900 | 851,824 | Apr 11 05:13 PM | | CORNELIUS JAMES M | Director | Apr 02 | Sale | 41.59 | 10,000 | 415,900 | 861,824 | Apr 02 05:03 PM | | CORNELIUS JAMES M | Director | Apr 01 | Sale | 41.09 | 10,000 | 410,900 | 871,824 | Apr 02 05:03 PM | | CORNELIUS JAMES M | Director | Mar 27 | Sale | 40.68 | 10,000 | 406,800 | 881,218 | Mar 28 04:31 PM | | CORNELIUS JAMES M | Director | Mar 26 | Sale | 40.62 | 10,000 | 406,200 | 891,218 | Mar 28 04:31 PM | | CORNELIUS JAMES M | Director | Mar 21 | Sale | 39.78 | 10,000 | 397,800 | 901,218 | Mar 22 04:16 PM | | CORNELIUS JAMES M | Director | Mar 20 | Sale | 39.78 | 10,000 | 397,800 | 911,218 | Mar 22 04:16 PM | | Cuss Francis M | SVP Research | Mar 13 | Option Exercise | 23.80 | 84,952 | 2,021,810 | 264,874 | Mar 14 04:26 PM | | Cuss Francis M | SVP Research | Mar 13 | Sale | 38.47 | 69,713 | 2,681,859 | 195,161 | Mar 14 04:26 PM | | Elicker John E | SVP Pub Affairs & Inv Relation | Mar 13 | Sale | 38.51 | 3,409 | 131,281 | 33,727 | Mar 14 04:26 PM | | CORNELIUS JAMES M | Director | Mar 13 | Sale | 38.34 | 10,000 | 383,400 | 921,218 | Mar 14 04:26 PM | | CORNELIUS JAMES M | Director | Mar 12 | Sale | 38.02 | 10,000 | 380,200 | 931,218 | Mar 14 04:26 PM | | CORNELIUS JAMES M | Director | Mar 08 | Sale | 37.41 | 10,000 | 374,100 | 941,218 | Mar 11 04:28 PM | | ANDREOTTI LAMBERTO | Chief Executive Officer | Mar 07 | Option Exercise | 0.00 | 330,160 | 0 | 739,611 | Mar 11 04:33 PM | | Schmukler Louis S | Pres., Global Mfg. & Supply | Mar 07 | Option Exercise | 0.00 | 2,528 | 0 | 12,445 | Mar 11 04:37 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Mar 07 | Option Exercise | 0.00 | 69,542 | 0 | 142,348 | Mar 11 04:37 PM | | Cuss Francis M | SVP Research | Mar 07 | Option Exercise | 0.00 | 45,017 | 0 | 197,975 | Mar 11 04:40 PM | | Caldarella Joseph C | SVP & Controller | Mar 07 | Option Exercise | 0.00 | 20,808 | 0 | 78,584 | Mar 11 04:40 PM | | LEUNG SANDRA | General Counsel & Secretary | Mar 07 | Option Exercise | 0.00 | 81,203 | 0 | 228,185 | Mar 11 04:44 PM | | DANIELS BRIAN | SVP Global Dev & Med Affairs | Mar 07 | Option Exercise | 0.00 | 42,070 | 0 | 94,942 | Mar 11 04:43 PM | | Caforio Giovanni | Pres., US Pharmaceuticals | Mar 07 | Option Exercise | 0.00 | 15,482 | 0 | 68,493 | Mar 11 04:47 PM | | Cazala Beatrice J | EVP Commercial Operations | Mar 07 | Option Exercise | 13.77 | 179,678 | 2,474,000 | 387,221 | Mar 11 04:47 PM | | von Autenried Paul | SVP, Enterp. Services & CIO | Mar 07 | Option Exercise | 0.00 | 21,975 | 0 | 63,619 | Mar 11 04:50 PM | | Moed Samuel J | SVP, Strat Plan & Analysis | Mar 07 | Option Exercise | 0.00 | 14,425 | 0 | 25,308 | Mar 11 04:50 PM | | Elicker John E | SVP Pub Affairs & Inv Relation | Mar 07 | Option Exercise | 0.00 | 15,169 | 0 | 40,764 | Mar 11 04:50 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Mar 07 | Option Exercise | 0.00 | 132,390 | 0 | 247,731 | Mar 11 04:50 PM | | CORNELIUS JAMES M | Director | Mar 07 | Sale | 37.67 | 10,000 | 376,700 | 951,218 | Mar 11 04:28 PM | | Cazala Beatrice J | EVP Commercial Operations | Mar 07 | Sale | 37.61 | 83,750 | 3,149,838 | 266,245 | Mar 11 04:47 PM | | Cazala Beatrice J | EVP Commercial Operations | Mar 06 | Option Exercise | 0.00 | 3,595 | 0 | 208,876 | Mar 07 04:05 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Mar 04 | Option Exercise | 0.00 | 7,453 | 0 | 119,206 | Mar 05 04:55 PM | | LEUNG SANDRA | General Counsel & Secretary | Mar 04 | Option Exercise | 0.00 | 3,980 | 0 | 148,465 | Mar 05 04:54 PM | | DANIELS BRIAN | SVP Global Dev & Med Affairs | Mar 04 | Option Exercise | 0.00 | 1,870 | 0 | 53,569 | Mar 05 04:54 PM | | ANDREOTTI LAMBERTO | Chief Executive Officer | Mar 04 | Option Exercise | 0.00 | 7,453 | 0 | 412,524 | Mar 05 04:54 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Mar 03 | Option Exercise | 0.00 | 46,365 | 0 | 135,794 | Mar 05 04:55 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Mar 03 | Option Exercise | 0.00 | 2,487 | 0 | 73,563 | Mar 05 04:24 PM | | Cuss Francis M | SVP Research | Mar 03 | Option Exercise | 0.00 | 3,753 | 0 | 154,351 | Mar 05 04:26 PM | | Caldarella Joseph C | SVP & Controller | Mar 03 | Option Exercise | 0.00 | 2,379 | 0 | 58,761 | Mar 05 04:26 PM | | Caforio Giovanni | Pres., US Pharmaceuticals | Mar 03 | Option Exercise | 0.00 | 1,851 | 0 | 53,701 | Mar 05 04:26 PM | | von Autenried Paul | SVP, Enterp. Services & CIO | Mar 03 | Option Exercise | 0.00 | 2,422 | 0 | 42,547 | Mar 05 04:27 PM | | Elicker John E | SVP Pub Affairs & Inv Relation | Mar 03 | Option Exercise | 0.00 | 1,851 | 0 | 26,159 | Mar 05 04:27 PM | | Moed Samuel J | SVP, Strat Plan & Analysis | Mar 03 | Option Exercise | 0.00 | 1,936 | 0 | 11,594 | Mar 05 04:27 PM | | LEUNG SANDRA | General Counsel & Secretary | Mar 03 | Option Exercise | 0.00 | 4,793 | 0 | 146,271 | Mar 05 04:54 PM | | DANIELS BRIAN | SVP Global Dev & Med Affairs | Mar 03 | Option Exercise | 0.00 | 2,691 | 0 | 52,701 | Mar 05 04:54 PM | | ANDREOTTI LAMBERTO | Chief Executive Officer | Mar 03 | Option Exercise | 0.00 | 10,344 | 0 | 409,335 | Mar 05 04:54 PM | | Caforio Giovanni | Pres., US Pharmaceuticals | Feb 27 | Sale | 37.08 | 12,150 | 450,522 | 51,850 | Feb 27 04:08 PM | | CORNELIUS JAMES M | Director | Feb 26 | Sale | 36.44 | 10,000 | 364,400 | 1,061,218 | Feb 27 04:08 PM | | CORNELIUS JAMES M | Director | Feb 25 | Sale | 36.71 | 10,000 | 367,100 | 1,071,218 | Feb 27 04:08 PM | | Caldarella Joseph C | SVP & Controller | Feb 20 | Option Exercise | 25.13 | 40,308 | 1,012,920 | 93,967 | Feb 20 04:12 PM | | Caldarella Joseph C | SVP & Controller | Feb 20 | Sale | 36.87 | 37,585 | 1,385,759 | 56,382 | Feb 20 04:12 PM | | CORNELIUS JAMES M | Director | Feb 13 | Sale | 36.15 | 10,000 | 361,500 | 1,101,218 | Feb 13 05:09 PM | | CORNELIUS JAMES M | Director | Feb 12 | Sale | 36.68 | 10,000 | 366,800 | 1,111,218 | Feb 13 05:09 PM | | Elicker John E | SVP Pub Affairs & Inv Relation | Feb 11 | Option Exercise | 28.11 | 16,875 | 474,356 | 39,572 | Feb 11 04:08 PM | | Elicker John E | SVP Pub Affairs & Inv Relation | Feb 11 | Sale | 36.97 | 15,264 | 564,359 | 24,308 | Feb 11 04:08 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Feb 08 | Option Exercise | 20.81 | 266,082 | 5,536,826 | 314,134 | Feb 11 04:08 PM | | SIGAL ELLIOT | EVP, CSO & President R&D | Feb 08 | Sale | 36.79 | 224,705 | 8,266,897 | 89,429 | Feb 11 04:08 PM | | CORNELIUS JAMES M | Director | Feb 07 | Sale | 36.42 | 10,000 | 364,200 | 1,121,218 | Feb 08 04:30 PM | | CORNELIUS JAMES M | Director | Feb 06 | Sale | 36.51 | 10,000 | 365,100 | 1,131,218 | Feb 08 04:30 PM | | LEUNG SANDRA | General Counsel & Secretary | Feb 05 | Option Exercise | 23.14 | 19,310 | 446,833 | 158,258 | Feb 05 04:18 PM | | LEUNG SANDRA | General Counsel & Secretary | Feb 05 | Sale | 36.87 | 16,780 | 618,679 | 141,478 | Feb 05 04:18 PM | | CAMPBELL LEWIS B | Director | Feb 04 | Option Exercise | 25.51 | 3,500 | 89,285 | 3,500 | Feb 05 04:06 PM | | von Autenried Paul | SVP & CIO | Feb 04 | Option Exercise | 25.57 | 56,212 | 1,437,227 | 90,425 | Feb 05 04:18 PM | | von Autenried Paul | SVP & CIO | Feb 04 | Sale | 36.67 | 50,300 | 1,844,501 | 40,125 | Feb 05 04:18 PM | | CAMPBELL LEWIS B | Director | Feb 04 | Sale | 36.77 | 3,500 | 128,695 | 0 | Feb 05 04:06 PM | | DANIELS BRIAN | SVP Global Dev & Med Affairs | Jan 31 | Sale | 36.22 | 12,000 | 434,640 | 50,010 | Jan 31 04:54 PM | | GLIMCHER LAURIE H M.D. | Director | Jan 30 | Option Exercise | 25.60 | 11,000 | 281,560 | 11,000 | Jan 30 04:16 PM | | GLIMCHER LAURIE H M.D. | Director | Jan 30 | Sale | 36.40 | 11,000 | 400,400 | 0 | Jan 30 04:16 PM | | CORNELIUS JAMES M | Director | Jan 29 | Sale | 36.53 | 10,000 | 365,300 | 1,141,218 | Jan 30 04:06 PM | | Caforio Giovanni | Pres., US Pharmaceuticals | Jan 28 | Option Exercise | 28.67 | 22,500 | 645,075 | 84,350 | Jan 28 04:32 PM | | Caforio Giovanni | Pres., US Pharmaceuticals | Jan 28 | Sale | 36.19 | 20,350 | 736,467 | 64,000 | Jan 28 04:32 PM | | CORNELIUS JAMES M | Director | Jan 28 | Sale | 36.43 | 10,000 | 364,300 | 1,151,218 | Jan 30 04:06 PM | | CORNELIUS JAMES M | Director | Jan 25 | Sale | 36.32 | 10,000 | 363,200 | 1,161,218 | Jan 28 04:11 PM | | CORNELIUS JAMES M | Director | Jan 24 | Sale | 35.78 | 10,000 | 357,811 | 1,171,218 | Jan 28 04:11 PM | | CORNELIUS JAMES M | Director | Jan 17 | Sale | 34.33 | 10,000 | 343,300 | 1,181,218 | Jan 18 04:40 PM | | CORNELIUS JAMES M | Director | Jan 16 | Sale | 34.33 | 10,000 | 343,300 | 1,191,218 | Jan 18 04:40 PM | | CORNELIUS JAMES M | Director | Jan 08 | Sale | 33.58 | 10,000 | 335,800 | 1,201,218 | Jan 09 04:15 PM |
|
 |
|
|
 |
|